QurAlis
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
100 Cambridgepark Dr Fl 5, Cambridge, Ma...Phone Number
(781) 816-7031Website
www.quralis.comRevenue
$30.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About QurAlis
QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. QurAlis' proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a deep pipeline of antisense oligonucleotides and small molecule programs including addressing sub-forms of ALS that account for the majority of ALS patients.Explore more
QurAlis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is QurAlis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if QurAlis is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on QurAlis recently announced quarterly report
Click to see if QurAlis had a recent Job posting/layoffs
QurAlis, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if QurAlis has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once QurAlis has new funding data
Congratulate Masked Content for being promoted to Masked Content at QurAlis
Product Launch: Get notified when QurAlis launches new products
Recommended Actions
Reach out to Masked Content who joined QurAlis as Masked Content
Find 2 more new buyers
Compare Similar Companies to QurAlis
Compare insights from companies similar to QurAlis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
51-200
Private
$147.5M
2018
RR
Renuka RamanathanVice President Head of Corporate & Business Development
Company Profile Activity
Activity Insights
QurAlis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
QurAlis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about QurAlis.
QurAlis financials insights
Gather financial insights about QurAlis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$42M
2023
Series B
$88M
2025
Debt
$20M
QurAlis Tech Stack
A closer look at the technologies used by QurAlis
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Events
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Person-Based
QurAlis News & Media
QurAlis Announces New Global Headquarters
CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced the opening of its new global corporate headquarters in Cambridge, MA. The company’s new 30,000 square foot state-of-the-art research facility and office space located at 35 Cambridgepark Drive (“35 CPD”), doublesQuiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X SyndromeQurAlis Announces Exclusive License on Novel Mechanism for Fragile X Syndrome (FXS) to Enable Development of First Potential Disease-Modifying Therapy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced it has entered into an exclusive license agreement with UMass Chan Medical School (“UMass Chan”) on a novel RNA-targeted mechanism confirmed to restore functional protein for Fragile X syndrome (FXS). Fragile X sy
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding QurAlis
Sign Up For FreeTo access detailed company insights
QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. QurAlis' proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations.... Read More
